Ipratropium bromide HFA-134a inhalation aerosol

DRUG2 trials

Sponsors

Boehringer Ingelheim

Conditions

Pulmonary Disease, Chronic Obstructive

Phase 2

Trial to Determine the Comparability of Ipratropium Bromide Hydrofluoroalkane (HFA)-134a Inhalation Aerosol to ATROVENT® Chlorofluorocarbon (CFC) Inhalation Aerosol, in Patients With Chronic Obstructive Pulmonary Disease (COPD)

CompletedNCT02236169

Boehringer IngelheimPulmonary Disease, Chronic Obstructive

Start: 2000-10-31Updated: 2014-09-10

Study of the Comparability of Ipratropium Bromide Hydrofluoroalkane (HFA)-134a Inhalation Aerosol to the Market Standard, Atrovent® Chlorofluorocarbon (CFC) Inhalation Aerosol, in Patients With Chronic Obstructive Pulmonary Disease

CompletedNCT02260011

Boehringer IngelheimPulmonary Disease, Chronic Obstructive

Start: 2000-10-31Updated: 2014-10-09